questionText: To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential impact of the reported withdrawal of the original formulation of Questran from the UK market on patients with bile acid malabsorption.
answerText: The Department is aware of the discontinuation of the original formulation of Questran (colestyramine 4g oral powder) sachets. Decisions to discontinue medicines are commercial decisions for manufacturers, and the Department does not have powers to requir...
heading: Colestyramine